Your browser version may not work well with NCBI's Web applications. More information here...
1: Blood. 2008 Jan 15;111(2):968-9.Click here to read Click here to read Links

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B.

PMID: 18182586 [PubMed - indexed for MEDLINE]

PMCID: PMC2200846

Patient Drug Information

  • Bortezomib (Velcade® )

    Bortezomib is used to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with at least one other medication. Bortezomib is also used to treat people with mantle cell ly...

  • Source: AHFS Consumer Medication Information